Tenaya Therapeutics, Inc.

NasdaqGS TNYA

Tenaya Therapeutics, Inc. Price to Sales Ratio (P/S) on February 05, 2025: 4.66

Tenaya Therapeutics, Inc. Price to Sales Ratio (P/S) is 4.66 on February 05, 2025, a -69.14% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Tenaya Therapeutics, Inc. 52-week high Price to Sales Ratio (P/S) is 24.19 on March 05, 2024, which is 418.52% above the current Price to Sales Ratio (P/S).
Tenaya Therapeutics, Inc. 52-week low Price to Sales Ratio (P/S) is 4.62 on February 04, 2025, which is -0.96% below the current Price to Sales Ratio (P/S).
Tenaya Therapeutics, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 13.15.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGS: TNYA

Tenaya Therapeutics, Inc.

CEO	Mr. Faraz Ali M.B.A.
IPO Date	July 30, 2021
Location	United States
Headquarters	171 Oyster Point Boulevard
Employees	140
Sector	Healthcare
Industries Biotechnology

Description

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

Key trends

Past 5 years